A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

June 8, 2026

Study Completion Date

June 8, 2026

Conditions
Venous Thromboembolism
Interventions
DRUG

REGN9933

Intravenous (IV) single dose administered

DRUG

REGN7508

IV single dose administered

DRUG

Placebo

IV single dose administered

Trial Locations (20)

1000

RECRUITING

Sveta Sofia Hospital, Sofia

10029

RECRUITING

Mount Sinai Medical Center, New York

10065

RECRUITING

Memorial Sloan Kettering, New York

33136

RECRUITING

Sylvester Comprehensive Cancer Center, Miami

48202

RECRUITING

Henry Ford Health System, Detroit

49100

RECRUITING

Rabin Medical Center, Petah Tikva

64239

RECRUITING

Tel Aviv Sourasky Medical Center, Tel Aviv

84101

RECRUITING

Soroka University Medical Center, Beersheba

91120

RECRUITING

Hadassah University Medical Center, Jerusalem

400006

RECRUITING

Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca, Cluj-Napoca

4244916

RECRUITING

Lanadio Medical Center, Netanya

5265601

RECRUITING

Sheba Medical Center, Ramat Gan

9103102

RECRUITING

Shaare Zedek Medical Center, Jerusalem

02115

RECRUITING

Brigham and Women's Hospital, Boston

N6A 4L6

RECRUITING

London Health Sciences Centre, London

L1G 2B9

RECRUITING

Lakeridge Health, Oshawa

M5G 2M9

RECRUITING

University Health Network, Toronto

SO16 6YD

RECRUITING

University hospital Southampton, Southampton

CF14 4CW

RECRUITING

Cardiff and Vale University Health Board - University Hospital Wales, Cardiff

NE1 4LP

RECRUITING

The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY